Gross Profit: Revenues from operations less the associated costs.
Amylyx Pharmaceuticals, Inc. (AMLX) Gross Profit data is not available for the most recently reported fiscal quarter, ending 2026-03-31.
| Income Statement Financials | |
-- |
|
$-41.28M |
|
-- |
|
|
Gross Profit |
-- |
$43.78M |
|
$-43.78M |
|
$2.50M |
|
$-41.28M |
|
$-41.28M |
|
$-41.28M |
|
$-41.28M |
|
$-41.28M |
|
$-41.28M |
|
$-43.78M |
|
$-44.29M |
|
110.56M |
|
110.56M |
|
$-0.37 |
|
$-0.37 |
|
| Balance Sheet Financials | |
$285.02M |
|
$0.21M |
|
$8.58M |
|
$293.60M |
|
$15.97M |
|
-- |
|
$4.48M |
|
$20.44M |
|
$273.16M |
|
$273.16M |
|
$273.16M |
|
111.03M |
|
| Cash Flow Statement Financials | |
$-36.88M |
|
$36.26M |
|
$3.22M |
|
$227.64M |
|
$230.12M |
|
$2.49M |
|
$6.12M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
17.85 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-40.88M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-15.11% |
|
-15.11% |
|
-14.06% |
|
-15.11% |
|
$2.46 |
|
$-0.37 |
|
$-0.33 |
|